The Business

Omni Innovation is a medical nutrition company that creates specialised food products that can be used by people with chronic and lifestyle diseases.

Omni’s products are independently validated and supervised by scientist collaborators to ensure customer safety and product effectiveness.

The Situation

CFSG was approached by Omni Innovation’s founders to assist the company to raise capital to assist it in accelerating the commercialisation of its foundation product, a clinically proven pre-meal shake for Type-2 diabetes.

The Process

CFSG took Omni through a structured capital raising process. This included a detailed analysis of the company’s capital requirements, the building of a targeted “hit list” of prospective investors and the development of comprehensive marketing and due diligence materials.

Omni was introduced to several ultra-high net worth individuals with existing interests in the healthcare and pharmaceutical sectors. In addition, CFSG was instrumental in assisting Omni to engage in discussions with Eagle Health Holdings. Eagle Health Holdings, a China-headquartered business, was particularly interested in distributing Omni’s diabetes product into mainland China, which is the largest market for Typre-2 diabetes in the world.

The Outcome

CFSG assisted Omni to negotiate and complete an agreement with Eagle Health to exclusively manufacture, market and distribute its diabetes product within mainland China. The deal included up-front licensing fees that provided Omni with ongoing working capital plus significant royalty payments.